Summary Regionally-administered, drug-loaded microspheres have a potential role in the treatment of renal tumours. Vasoactive agents, for example, angiotensin II, may allow selective delivery of microspheres to tumour. The present study defines the regional advantage that may be obtained from angiotensin II by quantifying tumour and normal kidney blood flow using radiolabelled microsphere renal perfusion studies and per-operative laser-doppler flow measurements. Angiotensin II increased microsphere distribution to tumour, relative to normal kidney, by a factor of four. This enhancement was associated with an absolute increase in tumour blood flow.
Renal carcinoma accounts for 2-3% of all adult malignancies. The majority of patients have no evidence of metastases at the time of initial presentation (Patel & Lavengood, 1978) ; nephrectomy is the treatment of choice. However, an alternative approach may be indicated in patients who are not considered suitable or fit for surgery and who have troublesome symptoms related to the primary tumour.
The results of systemic chemotherapy for renal neoplasms have been disappointing. Attempts to improve response rates have been limited to toxicity (Harris, 1983) . Attention has therefore turned to the concept of regional therapy with the intention of delivering high doses of therapeutic agents directly to tumour with minimal systemic exposure.
We have previously shown that the selective administration of cytotoxic-loaded albumin microspheres via the renal artery produces high concentrations of drug within the kidney Kerr et al., 1988) . Further Microsphere preparation Two aliquots of albumin microspheres were prepared for perfusion studies and radiolabelled with either 3''I or 'Tc.
Albumin microspheres for radiolabelling with "'lI were prepared as previously described (Willmott et al., 1985) . The microspheres were 25-351tm mean diameter as assessed by laser diffraction measurements. To 10 mg of microspheres (2 x 106 particles) were added 10 MBq of Na(`31I).
Albumin microspheres for radiolabelling with 9'Tc were prepared using a TCK5 kit (CIS) to produce 5 ml of 104 microspheres, The post-resection posterior images of the right kidney are illustrated in Figure 1 . The results of analysis of the ROI are shown in Table I (Lang, 1971; Kato et al., 1981) . Tumour shrinkage, symptomatic relief and reduced systemic exposure to the cytotoxic agents have been reported. Animal studies of regionally administered adriamycin-loaded albumin microspheres have revealed a high renal entrapment (97%), with subsequent release of drug by diffusion and biodegredation of the albumin matrix over 48 h, resulting in reduced systemic exposure to the antineoplastic agent Willmott et al., 1985) . Whilst these studies have been successful in so far as targeting the kidney is concerned, further measures are required to optimise the delivery of cytotoxic drugs to the tumour rather than normal renal tissue. Abrams (1964) demonstrated angiographically, in a patient with a hypernephroma, that an arterial infusion of epinephrine redistributes renal arterial blood flow. Ekelund et al. (1972) employed similar principles using angiotensin II to increase the diagnostic accuracy of renal angiography. On exposure to vasoactive agents, arterioles supplying normal tissue constrict whereas tumour blood vessels, which lack smooth muscle, remain dilated. This process therefore diverts renal blood flow and its contents away from normal tissue towards tumour. Lang (1970) used these techniques to deliver therapeutic radioactive pellets to renal tumours. Therefore these techniques allow second level targeting. Our previous pilot experiments, on three renal carcinoma patients, showed that the ratio of radiolabelled microspheres delivered to tumour compared with normal kidney, following an angiotensin II infusion, was 2.5:1, 3:1 and 7.3:1 respectively (unpublished data). Prior to the present study, the improvement in tumour: normal ratio, compared with pre-angiotensin II distribution, was not known. Our results suggest that angiotensin II may improve targeting of renal tumours by 4-fold.
Although radiolabelled microsphere distribution studies reveal changes in blood flow to tumour relative to normal tissue, they do not explain whether these observations are secondary to a decrease in blood flow to normal kidney, increased blood flow to tumour or a combination of both these factors. The introduction of laser-doppler flow equipment has allowed a dynamic study of tissue flow which has revealed an absolute increase in blood flow to tumour following angiotensin II infusion. Unfortunately, we did not possess two probes, therefore we were able to measure simultaneously blood flow to normal kidney and tumour.
In this experiment blood flow was studied using four techniques; in vivo perfusion scan, post-resection perfusion scan, tissue well gamma counting and laser-doppler measurements. It is interesting to note that all these methods produced similar results. Therefore in vivo renal arterial perfusion scintigraphy reasonably estimates the relative distribution of microspheres to tumour relative to normal kidney. However, the well gamma counts revealed a greater enhancement of tumour: normal ratio than the post-resection scan which, in turn, produced a higher ratio than the in vivo scan. These observations may be explained by increased scatter due to the kidney being further from the gamma camera on the in vivo scan compared with the post-resection scan. Furthermore, the gamma camera only gives a two dimensional analysis of the kidney (therefore the 'tumour' ROI includes normal tissues anterior and posterior to the tumour) whereas the well counts reflect activity in tumour alone. The well counts, therefore, probably give the most accurate reflection of tumour: normal kidney ratio enhancement. The accuracy of gamma camera imaging may be improved by employing tomographic techniques.
The albumin microspheres in normal kidney were seen to enibolise in the afferent arterioles and glomerular capillary loops. The mean biological half-time of these microspheres has been shown to be 2.4 days (Goldberg et al., 1991) and it is therefore likely that these glomeruli would undergo subsequent ischaemic necrosis. Angiotensin II should diminish this problem but it should be born in mind when considering the treatment of patients who have poor renal function or whose contralateral kidney is absent or abnormal.
In conclusion, angiotensin II infusion improves the targeting of regionally administered albumin microspheres to renal tumours. The use of cytotoxic loaded albumin microspheres in the management of renal tumours merits further study.
